Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    10401733 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Conditions: Cancer;   Pancreatic Cancer
Interventions: Procedure: Tumour Biopsy;   Other: Serial Collection of Plasma, Serum and Urine Samples
2 Not yet recruiting Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Radiation: Re-irradiation with SBRT
3 Not yet recruiting Safety and Efficacy Study of Five-fraction Stereotactic Body Radiation Therapy to Locally Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Device: Cyberknife
4 Not yet recruiting Combination of Stereotactic Body Radiation Therapy With S-1 for Treating Locally Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Other: combination of Cyberknife with S-1
5 Suspended Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
6 Completed Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Conditions: Histologically or Cytologically Confirmed Pancreatic Ca;   Unresectable or Borderline Resectable Pancreatic Ca
Intervention: Drug: Gemcitabine

Indicates status has not been verified in more than two years